Ji Yong, Zhang Han, Gong Fei-Long, Liang Jia-Long, Wang Sheng-Fei, Sang Yong-Hua, Zheng Ming-Feng
Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
Cell Death Dis. 2025 Feb 10;16(1):83. doi: 10.1038/s41419-025-07373-x.
Proline-rich 15 (PRR15) is a protein primarily known for its role in placental development. This study investigates the expression, functional significance, and underlying mechanisms of PRR15 in non-small cell lung cancer (NSCLC). Our findings demonstrate significantly elevated PRR15 expression in NSCLC tissues compared to normal lung parenchyma, with higher expression correlating with adverse clinical outcomes. Single-cell RNA sequencing confirmed PRR15 overexpression within the malignant tumor cell population. PRR15 expression was elevated in NSCLC tissues from locally treated patients and in a panel of primary and established NSCLC cells. PRR15 depletion using shRNA or CRISPR/Cas9-mediated knockout significantly suppressed proliferation and migration, while promoting apoptosis in various NSCLC cells. Conversely, ectopic PRR15 overexpression using a lentiviral construct enhanced cell proliferation and migration. Mechanistic investigations implicated PRR15 in the activation of the Akt-mTOR signaling pathway. Inhibition of PRR15 expression via shRNA or CRISPR/Cas9-mediated knockout resulted in decreased Akt and S6K phosphorylation, while PRR15 overexpression led to augmented Akt-S6K signaling in primary human NSCLC cells. In vivo studies using xenograft models further validated the oncogenic role of PRR15, demonstrating that PRR15 knockdown suppressed tumor growth and attenuated Akt-mTOR activation. These findings collectively highlight the potential of PRR15 as a novel oncogenic driver and therapeutic target in NSCLC.
富含脯氨酸的 15(PRR15)是一种主要因其在胎盘发育中的作用而闻名的蛋白质。本研究调查了 PRR15 在非小细胞肺癌(NSCLC)中的表达、功能意义及潜在机制。我们的研究结果表明,与正常肺实质相比,NSCLC 组织中 PRR15 的表达显著升高,且较高的表达与不良临床结果相关。单细胞 RNA 测序证实了恶性肿瘤细胞群体中 PRR15 的过表达。PRR15 在局部治疗患者的 NSCLC 组织以及一组原发性和已建立的 NSCLC 细胞中表达升高。使用 shRNA 或 CRISPR/Cas9 介导的敲除使 PRR15 缺失,显著抑制了多种 NSCLC 细胞的增殖和迁移,同时促进了细胞凋亡。相反,使用慢病毒构建体异位过表达 PRR15 增强了细胞增殖和迁移。机制研究表明 PRR15 参与了 Akt-mTOR 信号通路的激活。通过 shRNA 或 CRISPR/Cas9 介导的敲除抑制 PRR15 的表达导致 Akt 和 S6K 磷酸化降低,而 PRR15 的过表达导致原代人 NSCLC 细胞中 Akt-S6K 信号增强。使用异种移植模型的体内研究进一步验证了 PRR15 的致癌作用,表明 PRR15 的敲低抑制了肿瘤生长并减弱了 Akt-mTOR 的激活。这些发现共同突出了 PRR15 作为 NSCLC 中一种新型致癌驱动因子和治疗靶点的潜力。